Iovance Biotherapeutics Inc
NASDAQ:IOVA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.22
17.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc
Other Non-Cash Items
Iovance Biotherapeutics Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
Other Non-Cash Items
$93.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
31%
|
CAGR 10-Years
22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Non-Cash Items
$7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Non-Cash Items
-$419m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Non-Cash Items
$742.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Non-Cash Items
$480.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
Iovance Biotherapeutics Inc
Glance View
Iovance Biotherapeutics Inc. is navigating the intricate world of biotechnology with a bold mission: to develop innovative cancer immunotherapies that harness the power of the human immune system. Founded with the vision of transforming how cancer is treated, the company has journeyed through the challenging landscapes of medical research and regulatory scrutiny to bring forth groundbreaking treatments. At the heart of Iovance's strategy is its pioneering work in Tumor-Infiltrating Lymphocyte (TIL) therapy, a process that involves extracting, expanding, and then reinfusing a patient’s own immune cells to target and destroy cancerous tumors. This approach is not only novel but distinctly personal, as it effectively turns the patient's immune system into a bespoke tool against their cancer. The company's business model is centered around the successful clinical development and commercialization of these TIL therapies. As it advances its lead product candidates through critical phase trials, Iovance aims to secure FDA approval, which would transition these therapies from promising research to viable medical treatments. The financial backbone of Iovance comes from its ability to attract investors and establish partnerships, which fund the expensive and time-consuming research and development phase. Its revenue-generating potential will largely depend on the approval and subsequent adoption of its therapies, positioning it within the broader oncology treatment market, which is both highly competitive and highly lucrative. In this demanding arena, Iovance finds itself competing not just on the efficacy of treatments, but also on its capacity to scale production and navigate the complexities of healthcare pricing and reimbursement.
See Also
What is Iovance Biotherapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
93.7m
USD
Based on the financial report for Sep 30, 2024, Iovance Biotherapeutics Inc's Other Non-Cash Items amounts to 93.7m USD.
What is Iovance Biotherapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
22%
Over the last year, the Other Non-Cash Items growth was 21%. The average annual Other Non-Cash Items growth rates for Iovance Biotherapeutics Inc have been 6% over the past three years , 31% over the past five years , and 22% over the past ten years .
You don't have any saved screeners yet
